Photodynamic therapy with verteporfin: a new treatment in ophthalmology
- PMID: 15513441
- DOI: 10.1076/soph.16.4.201.10298
Photodynamic therapy with verteporfin: a new treatment in ophthalmology
Abstract
Photodynamic therapy (PDT) with verteporfin is a new treatment modality in ophthalmology that has previously shown its effectiveness in treatment of a variety of neoplastic pathologies. In this therapeutic approach, the photosensitizer verteporfin is activated by non-thermal laser light to obtain closure of neovascular structures. Preclinical and clinical studies have indicated that PDT is a safe, selective, and effective treatment for choroidal neovascularization in age-related macular degeneration. No significant damage to the neurosensory retina was found, which explains why PDT does not cause loss of visual acuity and may be used in a larger population than laser photocoagulation. This review summarizes the mechanisms of action of PDT, and the results of preclinical and clinical studies in ophthalmology.
Similar articles
-
Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.Surv Ophthalmol. 2000 Nov-Dec;45(3):195-214. doi: 10.1016/s0039-6257(00)00158-2. Surv Ophthalmol. 2000. PMID: 11094244 Review.
-
Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).Trans Am Ophthalmol Soc. 2008;106:357-82. Trans Am Ophthalmol Soc. 2008. PMID: 19277246 Free PMC article.
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.Arch Ophthalmol. 1999 Oct;117(10):1329-45. Arch Ophthalmol. 1999. PMID: 10532441 Clinical Trial.
-
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.Arch Ophthalmol. 2005 Apr;123(4):448-57. doi: 10.1001/archopht.123.4.448. Arch Ophthalmol. 2005. PMID: 15824216 Clinical Trial.
-
Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration.Arch Ophthalmol. 1999 Oct;117(10):1400-2. doi: 10.1001/archopht.117.10.1400. Arch Ophthalmol. 1999. PMID: 10532450 Review. No abstract available.
Cited by
-
Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration.J Biol Chem. 2016 Sep 2;291(36):18947-58. doi: 10.1074/jbc.M116.739722. Epub 2016 Jul 5. J Biol Chem. 2016. PMID: 27382053 Free PMC article.
-
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.Genes Dev. 2012 Jun 15;26(12):1300-5. doi: 10.1101/gad.192856.112. Epub 2012 Jun 7. Genes Dev. 2012. PMID: 22677547 Free PMC article.
-
Does Mechanocrine Signaling by Liver Sinusoidal Endothelial Cells Offer New Opportunities for the Development of Anti-fibrotics?Front Med (Lausanne). 2020 Jan 9;6:312. doi: 10.3389/fmed.2019.00312. eCollection 2019. Front Med (Lausanne). 2020. PMID: 31998732 Free PMC article. No abstract available.
-
Targeting YAP in malignant pleural mesothelioma.J Cell Mol Med. 2017 Nov;21(11):2663-2676. doi: 10.1111/jcmm.13182. Epub 2017 May 4. J Cell Mol Med. 2017. PMID: 28470935 Free PMC article.
-
Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin.J Biol Chem. 2011 Mar 4;286(9):7290-300. doi: 10.1074/jbc.M110.139915. Epub 2010 Dec 30. J Biol Chem. 2011. PMID: 21193398 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
